Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 11/20 | 0.58 |
| ▸ | MME | P08473 | 4/20 | 0.58 |
| ▸ | CPA1 | P15085 | 4/20 | 0.58 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.58 |
| ▸ | LNPEP | Q9UIQ6 | 6/20 | 0.56 |
| ▸ | ANPEP | P15144 | 5/20 | 0.56 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17274195 | 1.00 | ACE (0.58) | ACEMMECPA1ACE2LNPEP | |
| SCHEMBL18699897 | 1.00 | ACE (0.58) | ACEMMECPA1ACE2LNPEP | |
| SCHEMBL11799067 | 1.00 | ACE (0.58) | ACEMMECPA1ACE2LNPEP | |
| SCHEMBL29352065 | 0.91 | ACE (0.58) | ACEMMECPA1ACE2LNPEP | |
| SCHEMBL29351159 | 0.91 | ACE (0.60) | ACEMMECPA1ACE2LNPEP | |
| SCHEMBL30052882 | 0.91 | CTSD (0.58) | ACEMMECPA1ACE2LNPEP | |
| SCHEMBL29386631 | 0.91 | MME (0.50) | ACEMMECPA1ACE2LNPEP | |
| SCHEMBL29350566 | 0.91 | MME (0.50) | ACEMMECPA1ACE2LNPEP | |
| SCHEMBL29822653 | 0.90 | ACE (0.59) | ACEMMECPA1ACE2OPRM1 | |
| SCHEMBL31318683 | 0.88 | ACE (0.57) | ACEMMECPA1ACE2LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106456698-B | Synthesis of beta-arrestin effectors | 特维娜有限公司 | 2022-05-17 | — | — | CN | claimed |
| US-12433932-B2 | Ang (1-7) derivative oligopeptides for the treatment of pain | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4371556-A1 | ANGIOTENSIN(1-7) PHARMACEUTICAL COMPOSITIONS FOR INHALATION | Explicat Pharma GmbH (DE) | 2024-05-22 | — | — | EP | disclosed |
| CN-117120417-A | Methods and agents for stimulating mitochondrial turnover to treat diseases | 容量生物公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230226140-A1 | ANG (1-7) DERVIATIVE OLIGOPEPTIDES FOR THE TREATMENT OF PAIN | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-07-20 | — | — | US | disclosed |
| EP-3565575-B1 | ANG (1-7) DERIVATIVE OLIGOPEPTIDES FOR THE TREATMENT OF PAIN | UNIV ARIZONA (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-106456698-B | Synthesis of beta-arrestin effectors | 特维娜有限公司 | 2022-05-17 | — | — | CN | disclosed |
| US-20180016301-A1 | Synthesis of Beta-Arrestin Effectors | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2018-01-18 | — | — | US | disclosed |
| US-9611293-B2 | Synthesis of beta-arrestin effectors | TREVENA, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20150329593-A1 | Synthesis of Beta-Arrestin Effectors | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2015-11-19 | — | — | US | disclosed |
| US-3975365-A | Inhibitory octapeptides angiotensin II | G. D. SEARLE & CO. (US) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016301-A1 | Synthesis of Beta-Arrestin Effectors | ARRB1, ADRB1, ADRB3 | ACE 1568/4885MME 2361/4885CPA1 3030/4885 |
| US-20150329593-A1 | Synthesis of Beta-Arrestin Effectors | ARRB1, ADRB1, ADRB3 | ACE 1568/4885MME 2361/4885CPA1 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.